title: Brief demethylation step allows the conversion of adult human skin fibroblasts into insulin-secreting cells.
abstract: The differentiated state of mature cells of adult organisms is achieved and maintained through the epigenetic regulation of gene expression, which consists of several mechanisms including DNA methylation. The advent of induced pluripotent stem cell technology enabled the conversion of adult cells into any other cell type passing through a stable pluripotency state. However, indefinite pluripotency is unphysiological, inherently labile, and makes cells prone to culture-induced alterations. The direct conversion of one cell type to another without an intermediate pluripotent stage is also possible but, at present, requires the viral transfection of appropriate transcription factors, limiting its therapeutic potential. The aim of this study was to investigate whether it is possible to achieve the direct conversion of an adult cell by exposing it to a demethylating agent immediately followed by differentiating culture conditions. Adult human skin fibroblasts were exposed for 18 h to the DNA methyltransferase inhibitor 5-azacytidine, followed by a three-step protocol for the induction of endocrine pancreatic differentiation that lasted 36 d. At the end of this treatment, 35 ± 8.9% fibroblasts became pancreatic converted cells that acquired an epithelial morphology, produced insulin, and then released the hormone in response to a physiological glucose challenge in vitro. Furthermore, pancreatic converted cells were able to protect recipient mice against streptozotocin-induced diabetes, restoring a physiological response to glucose tolerance tests. This work shows that it is possible to convert adult fibroblasts into insulin-secreting cells, avoiding both a stable pluripotent stage and any transgenic modification.
authors.affiliation: Laboratory of Biomedical Embryology, UniStem, Center for Stem Cell Research, Università degli Studi di Milano, Italy.
authors.forename: Georgia
authors.initials: G
authors.lastname: Pennarossa
authors.forename: Sara
authors.initials: S
authors.lastname: Maffei
authors.forename: Marino
authors.initials: M
authors.lastname: Campagnol
authors.forename: Letizia
authors.initials: L
authors.lastname: Tarantini
authors.forename: Fulvio
authors.initials: F
authors.lastname: Gandolfi
authors.forename: Tiziana A L
authors.initials: TA
authors.lastname: Brevini
mesh_terms: D000328:Adult; D000818:Animals; D001374:Azacitidine / Q000494:pharmacology; D054338:Cell Transdifferentiation / Q000187:drug effects / Q000502:physiology*; D019175:DNA Methylation / Q000502:physiology*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D004797:Enzyme-Linked Immunosorbent Assay; D044127:Epigenesis, Genetic / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D005951:Glucose Tolerance Test; D006801:Humans; D007211:Indoles; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000166:cytology* / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D044968:Regenerative Medicine / Q000379:methods; D012867:Skin / Q000166:cytology*
chemical_list: D007211:Indoles; D007328:Insulin; C007293:DAPI; D015254:DNA Modification Methylases; D001374:Azacitidine
keywords: cell plasticity; pancreatic beta cell